Publications by authors named "Wu-Lung Chuang"
The impact of sodium-glucose cotransporter 2 inhibitors (SLGT2i) usage on reducing the risk of dementia remains uncertain. Our research seeks to establish the association between dementia risk and SLGT2 inhibitors among individuals with diabetes. This study relied on data from the Taiwan National Health Insurance Database (NHIRD), which was established in 1995 coinciding with the launch of the National Health Insurance (NHI) program by the Taiwanese government.
View Article and Find Full Text PDFAims: Evidence showed that SGLT2 inhibitors have greater protective effects against retinal diseases compared to other hypoglycemic agents. Thus, we explore the association between SGLT2 inhibitor usage and macular degeneration (MD) in Taiwanese patients with diabetes.
Methods: The National Health Insurance (NHI) program's claim data are released as the National Health Insurance Research Database (NHIRD).
Background: This study aimed to evaluate the long-term risk of CKD and renal function declines using a combination of diuretics and SGLT2i.
Methods: We selected the data of subjects who had at least two outpatient records or at least one inpatient record for DM treatment as the DM group from the National Health Insurance Research Database (NHIRD). Patients receiving versus not receiving SGLT2i were defined as the SGLT2i and non-SGLT2i cohorts, respectively.
Article Synopsis
- Vascular endothelial growth factor (VEGF) is important in kidney health as it helps with blood vessel growth and permeability, but blocking it can impede tumor growth.
- A study in Taiwan using extensive health data showed that patients treated with the anti-VEGF drug bevacizumab had a significantly higher risk of developing chronic kidney disease (CKD) compared to those who weren't treated.
- The research highlights the need for careful monitoring of kidney function in patients receiving bevacizumab, as the risk of CKD was found to be 1.35 times greater in these patients.
Intravitreal ranibizumab injection is associated with an increased risk of chronic kidney disease: a population-based study in Taiwan.
Naunyn Schmiedebergs Arch Pharmacol
July 2024
Systemic vascular endothelial growth factor (VEGF) blockade has been the top adjunctive chemotherapy since 1990. Anti-VEGF therapy has also been associated with worsened renal function in some patients. However, the association between patient outcomes and use of intravitreal VEGF inhibitors remains controversial.
View Article and Find Full Text PDF